GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback